» Articles » PMID: 24149912

Intracranial Hemorrhage Pattern in the Patients with Factor XIII Deficiency

Overview
Journal Ann Hematol
Specialty Hematology
Date 2013 Oct 24
PMID 24149912
Citations 5
Authors
Affiliations
Soon will be listed here.
Abstract

Intracranial hemorrhage (ICH) is one of the most severe and life-threatening manifestations occurring in the patients with factor XIII (F XIII) deficiency. The aim of this study was to describe the ICH pattern in the patients suffering from F XIII deficiency. In this case series, we investigated 38 patients with severe F XIII deficiency in south of Iran from January to May 2012. ICH pattern, neurologic complications, efficacy of treatment, and incidence of recurrence were reported. The site of ICH was intraparenchymal in 35 patients (92.1 %), subdural in 2 patients (5.2 %), and epidural hemorrhage in 1 patient (2.6 %). Besides, neurologic complications occurred in 21 patients (55.2 %), including locomotor disability in 8, psychological impairment in 7, mental disorders in 5, speech impairment in 4, and visual impairment in 2. Prophylaxis was started with a dose of 10 IU/kg Fibrogammin every 4-6 weeks for all the patients, except for one. All the patients on prophylaxis showed good response without any episodes of recurrence, except for one. The most frequent site of ICH in our patients was intraparenchymal. It seems that long-term prophylactic treatment with a dose of 10 IU/kg Fibrogammin could be effective in the prevention of CNS bleeding in the patients with F XIII deficiency. Moreover, all the patients with severe F XIII deficiency even without severe bleeding symptoms are recommended to undergo prophylactic treatment.

Citing Articles

Survival analysis of coagulation disorders: A retrospective study with a 5-year follow-up.

Jahangiri A, Ahmadi S, Rafieemehr H Heliyon. 2023; 9(6):e16376.

PMID: 37274668 PMC: 10238680. DOI: 10.1016/j.heliyon.2023.e16376.


Cost Efficacy of Rapid Whole Genome Sequencing in the Pediatric Intensive Care Unit.

Kobayashi E, Waldman B, Engorn B, Perofsky K, Allred E, Briggs B Front Pediatr. 2022; 9:809536.

PMID: 35141181 PMC: 8818891. DOI: 10.3389/fped.2021.809536.


Novel Factor XIII variant identified through whole-genome sequencing in a child with intracranial hemorrhage.

Briggs B, James K, Chowdhury S, Thornburg C, Farnaes L, Dimmock D Cold Spring Harb Mol Case Stud. 2018; 4(6).

PMID: 30404926 PMC: 6318776. DOI: 10.1101/mcs.a003525.


Clinical manifestations and management of life-threatening bleeding in the largest group of patients with severe factor XIII deficiency.

Naderi M, Dorgalaleh A, Alizadeh S, Tabibian S, Hosseini S, Shamsizadeh M Int J Hematol. 2014; 100(5):443-9.

PMID: 25230816 DOI: 10.1007/s12185-014-1664-1.


Current understanding in diagnosis and management of factor XIII deficiency.

Naderi M, Dorgalaleh A, Tabibian S, Alizadeh S, Eshghi P, Solaimani G Iran J Ped Hematol Oncol. 2014; 3(4):164-72.

PMID: 24575291 PMC: 3915454.